Merck & Co earnings were $3.2B for the trailing 12 months ending Jun 30, 2026, with -80.5% growth year over year. The latest MRK earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$1.3B, down 68.5% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, MRK reported annual earnings of $18.3B, with 6.6% growth.
MRK past earnings growth
How has MRK's earnings growth performed historically?
On MRK's earnings call on Aug 4, 2026, Merck & Co (NYSE: MRK) reported Q2 2026 earnings per share (EPS) of -$0.54, up 130.68% year over year. Total MRK earnings for the quarter were -$1.34 billion. In the same quarter last year, Merck & Co's earnings per share (EPS) was $1.76.
As of the last Merck & Co earnings report, Merck & Co is currently profitable. Merck & Co's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $3.17 billion, a 80.66% decrease year over year.
What was MRK's earnings growth in the past year?
As of Merck & Co's earnings date in Aug 4, 2026, Merck & Co's earnings has grown -80.46% year over year. This is 110.29 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 29.83%. MRK earnings in the past year totalled $3.17 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.